ECDC publishes data on hepatitis B and C surveillance and prevention in Europe
ECDC releases today two new reports on hepatitis B and C entitled ‘Surveillance and prevention of hepatitis B and C in Europe’ and ‘Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies’.
ECDC releases today two new reports on hepatitis B and C entitled ‘Surveillance and prevention of hepatitis B and C in Europe’ and ‘Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies’. Hepatitis surveillance is implemented in all Member States but varies considerably across countries. Universal vaccination programmes for HBV are implemented in 22 countries and seven countries have established targeted vaccination programmes.
The majority of the countries have implemented screenings for HBV in pregnant women; only four countries do not have such a programme. Half of the countries conduct screening programmes for hepatitis C, primarily for injecting drug users and prison inmates. Prevalence data on HBV and HCV remain scarce in many countries, both for the general population and groups-at-risk.The release of the reports coincides with a summit conference on hepatitis B and C, which will take place from 14 to 15 October in Brussels, Belgium.
The conference will bring together major stakeholders to analyse new and existing information and enable European policy makers and other stakeholders to formulate public policies in response to the epidemic of viral hepatitis in Europe.
Epidemiological update: Measles - monitoring European outbreaks, 18 August 2017
Romania and Italy have been experiencing large outbreaks of measles in 2017. Cases continue to be reported despite ongoing reinforced vaccination activities at the national level. All EU/EEA countries have reported measles cases this year, except for Latvia, Liechtenstein, Malta and Norway.Read more
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more